Pediatric Ophthalmology Research
Pediatric Myopia Treatment Study
Multicenter study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
AGE: 3-15 years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Myopia, Progressive
CONDITION: Myopia, Progressive
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center
LOCATION: University Hospitals Cleveland Medical Center
Learn More About This Research Study
For more information, please contact study coordinator, Loretta Szczotka-Flynn, OD, PhD at 216-216-844-5272 or complete the form below.
Study Purpose
The purpose of this research study is to determine if the investigational eye drop OT-101 can treat the progression of myopia.
Who Can Participate
Participants between 3 and 15 years old diagnosed with myopia may be eligible for this study.
- STUDY ID# 20210309
- NCT04770610